Christopher John A
Pharm Pat Anal. 2014;3(6):625-38. doi: 10.4155/ppa.14.46.
The orexin-1 and orexin-2 receptors are two G protein-coupled receptors that bind the neuropeptides orexin-A and orexin-B. Dual antagonism of the receptors by small molecules is clinically efficacious in the treatment of insomnia, where the most advanced molecule suvorexant has recently been approved. The scope of this article is to review the small molecule orexin receptor antagonist patent literature between January 2012 and January 2014.
食欲素-1和食欲素-2受体是两种与神经肽食欲素-A和食欲素-B结合的G蛋白偶联受体。小分子对这些受体的双重拮抗作用在失眠治疗中具有临床疗效,其中最先进的分子苏沃雷生最近已获批准。本文的范围是回顾2012年1月至2014年1月间小分子食欲素受体拮抗剂的专利文献。